Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01901172 · ClinicalTrials.gov registry record · Phase 1

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

A Phase 1 study, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
61
Enrollment target

NCT01901172 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 61 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01901172, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
61 participants
Enrollment target

Study Summary

This multicenter, open-label study will evaluate the effect of posaconazole on the pharmacokinetics of RO5503781, the relative bioavailability of two new RO5503781 formulations, and the effect of food on the pharmacokinetics of RO5503781 in patients with solid tumors.

Interventions

  • DRUG posaconazole
  • DRUG RO5503781

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2013-08
Est. Completion 2015-06
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

What the Registry Record Tells You About NCT01901172

The ClinicalTrials.gov registry entry for NCT01901172 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which posaconazole is the first listed.

NCT01901172 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01901172 about?

NCT01901172 is a clinical study titled "A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors". This multicenter, open-label study will evaluate the effect of posaconazole on the pharmacokinetics of RO5503781, the relative bioavailability of two new RO5503781 formulations, and the effect of food on the pharmacokinetics of RO5503781 in patients with solid tumors.

What is the current status of trial NCT01901172?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2013-08. Estimated completion is 2015-06.

What interventions are being tested in trial NCT01901172?

The interventions under investigation include: posaconazole (DRUG), RO5503781 (DRUG).

Who is sponsoring clinical trial NCT01901172?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.